[HTML][HTML] Outcome of Outpatient Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma and Relapsed and Refractory Hodgkin …
KA Al-Anazi, A Alshami, E Mutahar… - Journal of Stem …, 2023 - stemcelltherjournal.com
Background: Autologous hematopoietic stem cell transplants (HSCT) is the standard of care
for transplant-eligible patients with newly diagnosed multiple myeloma (MM) and patients …
for transplant-eligible patients with newly diagnosed multiple myeloma (MM) and patients …
[HTML][HTML] Introductory Chapter: Update on Multiple Myeloma
KA Al-Anazi - Recent Updates on Multiple Myeloma, 2023 - intechopen.com
Multiple myeloma (MM) is a heterogeneous and an incurable disease that is characterized
by periods of remission alternating with relapses or progressions that ultimately lead to …
by periods of remission alternating with relapses or progressions that ultimately lead to …
Bortezomib, lenalidomide and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma: the more is likely the better
M Mohty, F Malard, A Bazarbachi - Clinical Hematology …, 2020 - atlantis-press.com
The autologous hematopoietic cell transplantation (auto-HCT) procedure for multiple
myeloma (MM) comprises several key steps: induction, hematopoietic cell mobilization, high …
myeloma (MM) comprises several key steps: induction, hematopoietic cell mobilization, high …
[HTML][HTML] An Update on Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
KA Al-Anazi, Z Alshaibani… - Recent Updates on …, 2023 - intechopen.com
Over the past two decades, treatment of multiple myeloma (MM) has advanced dramatically.
However, despite the introduction of several lines of novel therapeutics, autologous …
However, despite the introduction of several lines of novel therapeutics, autologous …